HIDA Scan Market: Global Industry Analysis, Drivers, Statistics, Dynamics, Segmentation by Product, Indentation, End User, Region and Forecast (2025-2032)

The HIDA Scan Market is estimated to be valued at USD 300 Million in 2024. The market expected to reach USD 493.89 Million by 2032, exhibiting a compound annual growth rate (CAGR) of 6.43% from 2025 to 2032.
HIDA Scan Market Outlook
A HIDA (Hepatobiliary Iminodiacetic Acid) scan is an imaging test that uses a radioactive tracer to track the flow of bile from the liver to the small intestine, helping diagnose problems with the liver, gallbladder, and bile ducts. The rising incidents of liver and gallbladder diseases such as cholecystitis and obstruction of bile ducts are hugely affecting the HIDA Scan market for the Hepatobiliary Iminodiacetic Acid (HIDA) scans. This large-scale growth is predominantly the result of the evolution of nuclear medicine imaging techniques and an increasing preference for minimally invasive diagnostic methods. HIDA Scan Market growth includes the exorbitant costs associated with nuclear imaging as well as the poor availability of advanced imaging facilities in developing nations.

Recent developments in the HIDA Scan Market highlight advancements in diagnostic and critical care solutions. In October 2023, GE Healthcare introduced the CardioCare V100 Ventilator to improve portable critical care. In November 2023, Siemens Healthineers expanded its service network in Saudi Arabia to enhance technical support. In January 2024, Mindray Medical International opened a manufacturing facility in Kenya to boost affordable healthcare solutions, while Draegerwerk AG partnered with a UAE healthcare provider to implement a cloud-based patient monitoring system. These developments reflect the market's focus on innovation, accessibility, and real-time diagnostic improvements.To know about the Research Methodology :- Request Free Sample Report
HIDA Scan Market Dynamics
Advancements in imaging technology and increasing hepatobiliary disease cases

The HIDA Scan Market is driven by the increasing rate of gallbladder and liver diseases, increasing demand for non-invasive diagnostic procedures, and advancements in nuclear imaging technology. The growing adoption of SPECT and hybrid imaging systems has enhanced diagnostic accuracy, leading to higher acceptance rates. Additionally, the expansion of healthcare infrastructure, increased awareness of hepatobiliary disorders, and supportive government initiatives promoting early disease detection further propel market growth. The increasing senior population, which is more prone to biliary conditions, also contributes to the increasing demand for HIDA scans Market.

High costs, regulatory hurdles, and limited radiopharmaceutical availability challenge

The HIDA Scan Market faces several challenges, including the high cost of nuclear imaging systems, which limits accessibility, especially in developing regions. The limited availability of radiopharmaceuticals and strict regulatory approvals for their use also pose significant challenge. Additionally, a radioactive tracers used in HIDA scans requires efficient supply chain management. A shortage of trained nuclear medicine professionals further restricts the common acceptance of HIDA scans, impacting diagnostic efficiency in many regions.

AI integration, hybrid imaging adoption, and advancements in radiopharmaceuticals

The HIDA Scan Market is witnessing key trends, including the integration of AI and machine learning to enhance imaging accuracy and diagnostic efficiency. The acceptance of hybrid imaging techniques, such as SPECT/CT, is growing, improving hepatobiliary assessments. Additionally, there is a increasing demand for non-invasive and rapid diagnostic solutions, driven by advancements in radiopharmaceuticals. The market is also seeing increased investments in nuclear medicine infrastructure, particularly in emerging economies, expanding access to advanced diagnostic tools.
HIDA Scan Market Segment Analysis
Based on Product, HIDA Scan Market is segmented into radiopharmaceuticals, gamma camera, and others. In 2024, Radiopharmaceuticals segment dominated the competitive market and expected to hold the largest market shares over the forecast period. Radiopharmaceuticals are a critical component of HIDA scans, as they enable the visualization of the hepatobiliary system. These radioactive tracers, such as Technetium-99m-labeled iminodiacetic acid (Tc-99m IDA) compounds, help assess liver function, gallbladder abnormalities, and bile duct obstructions. The increasing demand for highly specific and short-half-life tracers has led to ongoing research in radiopharmaceutical development. Additionally, advancements in radio pharmacy logistics and distribution are improving accessibility.

Based on End User, the HIDA scan market is divided into hospitals, clinics and others. In 2024 Hospitals segment dominated the competitive market and expected to hold the largest market shares over the forecast period. Hospitals are the leading end users in the HIDA Scan Market, as they are main healthcare centers for diagnosing and treating hepatobiliary disorders. Equipped with advanced imaging systems like gamma cameras and SPECT scanners, hospitals perform HIDA scans to detect gallbladder dysfunction, bile duct obstruction, and liver function abnormalities.Based on Indentation, HIDA Scan Market is segmented into gallbladder disease, bile atresia, bile duct barrier and cholecystitis. In 2024, gallbladder diseases segment dominated the competitive market and expected to hold the largest market shares over the forecast period. The most common signal for HIDA scans is the diagnosis of the gallbladder, where it helps to assess the functionality of the gallbladder and detect conditions such as gallstones or acute cholecystitis. It is also used to evaluate bile atresia in assessing infants, bile duct barriers and liver function. The division is inspired by the increasing gallbladder-related diseases, making it a main application of HIDA scanning in clinical settings. As healthcare progresses, the demand for accurate clinical imaging for these signs is increasing.
HIDA Scan Market Regional Insights
North America dominated the market in 2024 and expected to hold the largest market shares over the forecast period. North America, Europe, Asia Pacific, and the Middle East and Africa are the four biggest regions when considering the global market for gall bladder treatment.

The largest market share is in North America due to the large number of patients suffering from gallbladder issues. Market growth has also been supported by a strong healthcare sector and high healthcare expenses. Large market stocks, because it is where major companies that deal in equipment for the use of radioactive imaging technologies are located. The leading companies within the market are also focusing on strategies such as partnerships.

Europe possesses the second largest market share for HIDA scans. Increased government funding towards research and development in the identification of chronic diseases is one of the primary causes of the rise in the gall bladder treatment sector in Europe. As a result of increased need for technologically sophisticated devices and the overall growth of the healthcare sector, Germany, France, and the United Kingdom are the top contributors to the gall bladder treatment market in Europe.

Asia Pacific has the fastest-growing market. The growth of this market in Asia Pacific has been led by drivers like increasing awareness of the treatment of the gall bladder, a huge population of patients, and enhanced health care infrastructure. With increasing government support for healthcare and increasing demand in the market for advanced imaging technologies, India is expected to have the most rapidly growing market.
HIDA Scan Market Competitive landscape
The HIDA Scan Market is competitive, with key players focusing on technological advancements, strategic collaborations, and product expansions. Major HIDA Scan companies in the market include GE Healthcare, Siemens Healthineers, Philips Healthcare, Toshiba Medical Systems, Bracco Diagnostic Inc., Digirad Corporation, DDD-Diagnostics A/S, and Cardinal Health, Inc. These companies are investing in radiopharmaceutical development, imaging system innovations, and AI-driven diagnostic tools to improve the accuracy and efficiency of hepatobiliary imaging. The market is witnessing a rise in partnerships and acquisitions to strengthen product portfolios and expand global reach. With the increasing prevalence of gallbladder and liver diseases, there is a growing demand for advanced nuclear imaging solutions, driving further research and development in the field. Additionally, regulatory approvals and advancements in gamma cameras and SPECT imaging are shaping the competitive dynamics of the market, allowing companies to gain a competitive edge.

1. GE Healthcare

GE Healthcare is a most prominent player in the HIDA scan market with vast knowledge of medical imaging technologies and radiopharmaceuticals. They supply advanced gamma cameras and CT scan systems that are usually applied for hepatobiliary imaging. Research and development activities have led to the development of high sensitivity detectors and AI-based imaging solutions for enhancing diagnostic accuracy concerning gallbladder and bile duct maladies.

2. Bracco Imaging

Bracco Imaging is an important player in the radiopharmaceutical component of the HIDA scan market, supplying contrast media and nuclear medicine tracers for hepatobiliary imaging. It has a demonstrated track record in the Production of high-quality technetium-based radiopharmaceuticals used in HIDA scans that are designed to assess gallbladder function and bile flow.
HIDA Scan Market Scope: Inquire before buying



HIDA Scan Market


Report Coverage
Details


Base Year:
2024
Forecast Period:
2025-2032


Historical Data:
2019 to 2024
Market Size in 2024:
USD 300 Mn.


Forecast Period 2025 to 2032 CAGR:
6.43%
Market Size in 2032:
USD 493.89 Mn.


 Segments Covered:
by Product
Radiopharmaceuticals
Gamma camera
Others


by Indentation
Cholecystitis
Bile duct obstruction
Biliary atresia
Postoperative complications
Assessment of liver transplant


by End User
Hospitals & clinics
Diagnostic centers
Others



HIDA Scan Market Regional Insights
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Australia and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Taiwan, Bangladesh, Pakistan)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)
South America (Brazil, Argentina Rest of South America)
HIDA Scan Market Key Players are:
North America
1. GE Healthcare (U.S)
2. Siemens Healthineers (U.S)
3. Digirad Corporation (U.S)
4. Bracco Diagnostic Inc. (U.S)
5. Houston Medical Imaging (U.S)
6. Buffalo MRI (U.S)
7. Cardinal Health, Inc. (U.S)

Europe
8. DDD-Diagnostics A/S (Germany)
9. Serac Imaging Systems (U.K)

Asia-Pacific
10. Toshiba Medical Systems Corporation (Japan)
11. Philips Healthcare (Netherlands)
Frequently Asked Questions:
1.What CAGR is the HIDA scan market projected to grow during forecast period?
Ans: The HIDA scan market is projected to grow at a 6.43% CAGR between 2025-2032.

2.Name the End User of HIDA scan market?
Ans: Diagnostic centers, hospitals and clinics, and others are the End Users of HIDA scan market.

3.Which region is lead to HIDA scan market?
Ans: The North Americas is projected to lead the HIDA scan market.

4.Which factors are adding the HIDA scan market growth?
Ans: Increasing healthcare expenditure and rising prevalence of gall bladder diseases are adding to the HIDA scan market growth.

5.Who are the key players in HIDA scan market?
Ans: The key players are Houston Medical Imaging (U.S), Bracco Diagnostic Inc. (U.S), Buffalo MRI (U.S), Siemens (U.S), DDD- Diagnostics A/S (Germany) etc.